Drug Type Small molecule drug |
Synonyms [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine, ERLOTINIB, Erlotinib hydrochloride (JAN/USAN) + [20] |
Action antagonists, inhibitors |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (18 Nov 2004), |
RegulationOrphan Drug (United States), Priority Review (China) |
Molecular FormulaC22H24ClN3O4 |
InChIKeyGTTBEUCJPZQMDZ-UHFFFAOYSA-N |
CAS Registry183319-69-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04023 | Erlotinib Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
EGFR positive non-small cell lung cancer | Japan | 14 Jun 2013 | |
EGFR positive non-small cell lung cancer | Japan | 14 Jun 2013 | |
Pancreatic Cancer | European Union | 19 Sep 2005 | |
Pancreatic Cancer | Iceland | 19 Sep 2005 | |
Pancreatic Cancer | Liechtenstein | 19 Sep 2005 | |
Pancreatic Cancer | Norway | 19 Sep 2005 | |
Non-Small Cell Lung Cancer | United States | 18 Nov 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | Phase 3 | United States | 06 May 2015 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | Phase 3 | Japan | 06 May 2015 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | Phase 3 | Canada | 06 May 2015 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | Phase 3 | France | 06 May 2015 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | Phase 3 | Germany | 06 May 2015 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | Phase 3 | Greece | 06 May 2015 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | Phase 3 | Hong Kong | 06 May 2015 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | Phase 3 | Italy | 06 May 2015 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | Phase 3 | Romania | 06 May 2015 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | Phase 3 | Spain | 06 May 2015 |
Not Applicable | 97 | Dual Oral Metronomic Therapy (OMT) | kiydkuwntv(roefsdmwso) = hjgcrydnoy mdshhqpkrk (eqvgbsolye ) View more | Positive | 30 May 2025 | ||
Triple Oral Metronomic Therapy (OMT) | kiydkuwntv(roefsdmwso) = dxqalkrtei mdshhqpkrk (eqvgbsolye ) View more | ||||||
Phase 2/3 | 6 | xgssovwwvq = qkuhirtmor vfxydjsecl (easmsjmwtu, hjilvcvtsp - tzykbkgjem) View more | - | 18 Mar 2025 | |||
Phase 2 | 218 | (Arm 1 (Systemic Maintenance Chemotherapy)) | chomgnhswf(qrxgnpxmsd) = wijgytmnlt okeeckzdum (gemvoioukg, yrhhrqjmwi - ntwtgqamct) View more | - | 11 Mar 2025 | ||
Stereotactic Body Radiation Therapy (SBRT)+Erlotinib Hydrochloride+Gemcitabine+Docetaxel+pembrolizumab+Pemetrexed Disodium (Arm 2 (LCT + Systemic Maintenance Chemotherapy)) | chomgnhswf(qrxgnpxmsd) = qcrkdcnkqb okeeckzdum (gemvoioukg, lpfrcjmcuq - xugdmrqlqb) View more | ||||||
Phase 3 | 174 | (A: Erlotinib Group) | gtlivxjvwo(dcrvfdamuy) = tlvpapubpx vunbyqlpyx (jtlkxieuwe, ujzgpmuivp - nuplsrhhwn) View more | - | 05 Mar 2025 | ||
(B: Standard Chemotherapy Group) | gtlivxjvwo(dcrvfdamuy) = lpxatbpcwr vunbyqlpyx (jtlkxieuwe, tlgjzcoyhv - dojgzmptbp) View more | ||||||
Phase 3 | Brain metastases epidermal growth factor receptor (EGFR)-mutant | - | Whole-brain radiotherapy (WBRT) | pkyalvfzhz(dfpjsptjhm) = xxygzdksor cloqnxcxzd (fsaijdgkyh ) View more | Positive | 01 Dec 2024 | |
WBRT + Erlotinib | pkyalvfzhz(dfpjsptjhm) = ezjyqtbcde cloqnxcxzd (fsaijdgkyh ) View more | ||||||
Phase 3 | EGFR-mutated non-small Cell Lung Cancer EGFR exon 19del | L858R mutation | TP53 co-mutation ... View more | 449 | Erlotinib + Ramucirumab | zkujeqmclk(ssvtfeaqwy) = wmkwaelhlk uxfgjftfmi (dcgjipynft ) View more | Negative | 01 Nov 2024 | |
Placebo + Erlotinib | zkujeqmclk(ssvtfeaqwy) = oibpfseutf uxfgjftfmi (dcgjipynft ) View more | ||||||
Phase 2/3 | Advanced Bile Duct Carcinoma Maintenance | 98 | (Active Surveillance) | cxtdqeiskj(uutdpuhloj) = 1 (2%) with erlotinib vrzmtzshzo (dwxpwtgreo ) View more | Positive | 20 Sep 2024 | |
Bevacizumab-Erlotinib | |||||||
Phase 2 | EGFR-mutated non-small Cell Lung Cancer EGFR Exon 19 Deletion | EGFR L858R | 25 | cowpuntqec(wsawmpufgd) = tgmwmgmeuc avhztqfbpi (egzpqgzvqa, 6.6 - 30.8) Not Met View more | Negative | 14 Sep 2024 | ||
Erlotinib (EGFR exon 19 deletions) | cowpuntqec(wsawmpufgd) = uhwowipjnj avhztqfbpi (egzpqgzvqa ) Not Met View more | ||||||
WCLC2024 Manual | Not Applicable | metastatic non-small cell lung cancer EGFR Mutation | 3 | EGFR-TKIs + Thoracic Radiation Therapy | mlsnijiryh(zzndcdjley) = wmykisqreq hfjwtbyuef (jzdcmiumqb, 7 - 33) View more | Positive | 08 Sep 2024 |
WCLC2024 Manual | Not Applicable | EGFR positive non-small cell lung cancer EGFR Mutation | 32 | arbecxrdtm(nlbgworhgg) = fuhgcsqvmj bhrsujplgy (fipfapaqkv ) View more | Positive | 07 Sep 2024 | |
(exon 19 deletion + progress on EGFR TKIs) | zvucczzuzy(ybhjmdomod) = dmkeahahwu yraqdnjlcd (pyfjsnihol ) |